Clinical Trial Matcher

NCT06874231

Brain Connectivity Marker for Alzheimer's Disease

Recruiting · Not specified · Karolinska Institutet · registry updated 2025-03-17

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).

Inclusion

  • Inclusion criteria for subjects with subjective cognitive complaints:
  • MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30.
  • Absence of cognitive impairment.
  • Memory problems reported by the participant/family member.
  • Do not fulfill criteria for mild cognitive impairment or dementia.
  • Must speak and understand Swedish.

Exclusion

  • Alcohol or drug abuse.
  • Unstable somatic disease or organ failure.
  • Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram.
  • In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.

Open NCT06874231 on ClinicalTrials.govAll conditions